---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-006209"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:54:39.072449+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Dermata Therapeutics Q1 cash $8.8M; FDA agrees CMC supports Phase 3 for acne drug DMT310

## Summary
- Cash and cash equivalents $8.8M as of March 31, 2023, up from $6.2M at Dec 31, 2022.
- Raised $5.0M gross from March 2023 public offering of common stock and warrants.
- FDA agreed that CMC procedures are sufficient to initiate Phase 3 studies of DMT310 for moderate-to-severe acne.
- R&D expenses $1.2M for Q1 2023, down from $1.6M in Q1 2022; G&A $1.1M vs $1.2M.
- Expects cash to fund operations into Q1 2024; awaiting FDA feedback on End of Phase 2 meeting by June 2023.

## SEC filing metadata
- accession: 0001654954-23-006209
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000165495423006209/0001654954-23-006209-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000165495423006209/drma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-006209
- JSON: https://secwatch.observer/filing/0001654954-23-006209.json
- Plain text: https://secwatch.observer/filing/0001654954-23-006209.txt

## Key facts
- Earnings Releases
  Dermata Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023.
  - Period: the first quarter ended March 31, 2023
  - Result: reported results
  source text: reported financial results for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1853816/000165495423006209/0001654954-23-006209-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.